REGENERON PHARMACEUTICALS, INC. Revenue
REGENERON PHARMACEUTICALS, INC. (REGN) reported Revenue of $4.29 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-07-30
- REGENERON PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $4.29B, a 16.73% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $3.61B, a 19.04% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $3.88B, a 2.51% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $3.75B, a 0.90% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $14.34B, a 0.99% increase from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $14.20B, a 8.27% increase from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $13.12B, a 7.76% increase from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $12.17B, a 24.26% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.29B 10-Q · filed 2026-07-30 | $7.90B 10-Q · filed 2026-07-30 | $11.78B derived: sum of 3 quarters · filed 2026-07-30 | $15.53B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $3.61B 10-Q · filed 2026-04-29 | $7.49B derived: sum of 2 quarters · filed 2026-04-29 | $11.24B derived: sum of 3 quarters · filed 2026-04-29 | $14.92B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $3.88B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $7.64B derived: sum of 2 quarters · filed 2026-02-04 | $11.31B derived: sum of 3 quarters · filed 2026-07-30 | $14.34B 10-K · filed 2026-02-04 | ||||
| 2025-09-30 | $3.75B 10-Q · filed 2025-10-28 | $7.43B derived: sum of 2 quarters · filed 2026-07-30 | $10.46B 10-Q · filed 2025-10-28 | $14.25B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $3.68B 10-Q · filed 2026-07-30 | $6.70B 10-Q · filed 2026-07-30 | $10.49B derived: sum of 3 quarters · filed 2026-07-30 | $14.21B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $3.03B 10-Q · filed 2026-04-29 | $6.82B derived: sum of 2 quarters · filed 2026-04-29 | $10.54B derived: sum of 3 quarters · filed 2026-04-29 | $14.09B derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2024-12-31 | $3.79B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $7.51B derived: sum of 2 quarters · filed 2026-02-04 | $11.06B derived: sum of 3 quarters · filed 2026-02-04 | $14.20B 10-K · filed 2026-02-04 | ||||
| 2024-09-30 | $3.72B 10-Q · filed 2025-10-28 | $7.27B derived: sum of 2 quarters · filed 2025-10-28 | $10.41B 10-Q · filed 2025-10-28 | $13.85B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-06-30 | $3.55B 10-Q · filed 2025-08-01 | $6.69B 10-Q · filed 2025-08-01 | $10.13B derived: sum of 3 quarters · filed 2026-02-04 | $13.49B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-03-31 | $3.15B 10-Q · filed 2025-04-29 | $6.58B derived: sum of 2 quarters · filed 2026-02-04 | $9.94B derived: sum of 3 quarters · filed 2026-02-04 | $13.10B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2023-12-31 | $3.43B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $6.80B derived: sum of 2 quarters · filed 2026-02-04 | $9.96B derived: sum of 3 quarters · filed 2026-02-04 | $13.12B 10-K · filed 2026-02-04 | ||||
| 2023-09-30 | $3.36B 10-Q · filed 2024-10-31 | $6.52B derived: sum of 2 quarters · filed 2024-10-31 | $9.68B 10-Q · filed 2024-10-31 | $13.10B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-06-30 | $3.16B 10-Q · filed 2024-08-01 | $6.32B 10-Q · filed 2024-08-01 | $9.73B derived: sum of 3 quarters · filed 2025-02-05 | $12.67B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-03-31 | $3.16B 10-Q · filed 2024-05-02 | $6.58B derived: sum of 2 quarters · filed 2025-02-05 | $9.51B derived: sum of 3 quarters · filed 2025-02-05 | $12.37B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2022-12-31 | $3.41B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-05 | $6.35B derived: sum of 2 quarters · filed 2025-02-05 | $9.21B derived: sum of 3 quarters · filed 2025-02-05 | $12.17B 10-K · filed 2025-02-05 | ||||
| 2022-09-30 | $2.94B 10-Q · filed 2023-11-02 | $5.79B derived: sum of 2 quarters · filed 2023-11-02 | $8.76B 10-Q · filed 2023-11-02 | $13.71B derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-06-30 | $2.86B 10-Q · filed 2023-08-03 | $5.82B 10-Q · filed 2023-08-03 | $10.77B derived: sum of 3 quarters · filed 2024-02-05 | $14.23B derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-03-31 | $2.97B 10-Q · filed 2023-05-04 | $7.92B derived: sum of 2 quarters · filed 2024-02-05 | $11.37B derived: sum of 3 quarters · filed 2024-02-05 | $16.51B derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2021-12-31 | $4.95B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-05 | $8.40B derived: sum of 2 quarters · filed 2024-02-05 | $13.54B derived: sum of 3 quarters · filed 2024-02-05 | $16.07B 10-K · filed 2024-02-05 | ||||
| 2021-09-30 | $3.45B 10-Q · filed 2022-11-03 | $8.59B derived: sum of 2 quarters · filed 2022-11-03 | $11.12B 10-Q · filed 2022-11-03 | $13.54B derived: sum of 4 quarters · filed 2022-11-03 | ||||
| 2021-06-30 | $5.14B 10-Q · filed 2022-08-03 | $7.67B 10-Q · filed 2022-08-03 | $10.09B derived: sum of 3 quarters · filed 2022-08-03 | $12.38B derived: sum of 4 quarters · filed 2022-08-03 | ||||
| 2021-03-31 | $2.53B 10-Q · filed 2022-05-04 | $4.95B derived: sum of 2 quarters · filed 2022-05-04 | $7.25B derived: sum of 3 quarters · filed 2022-05-04 | $9.20B derived: sum of 4 quarters · filed 2022-05-04 | ||||
| 2020-12-31 | $2.42B 10-K · filed 2021-02-08 | $4.72B derived: sum of 2 quarters · filed 2021-11-04 | $6.67B derived: sum of 3 quarters · filed 2021-11-04 | $8.50B 10-K · filed 2023-02-06 | ||||
| 2020-09-30 | $2.29B 10-Q · filed 2021-11-04 | $4.25B derived: sum of 2 quarters · filed 2021-11-04 | $6.07B 10-Q · filed 2021-11-04 | $7.94B derived: sum of 4 quarters · filed 2021-11-04 | ||||
| 2020-06-30 | $1.95B 10-Q · filed 2021-08-05 | $3.78B 10-Q · filed 2021-08-05 | $5.64B derived: sum of 3 quarters · filed 2021-08-05 | $7.39B derived: sum of 4 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | $1.83B 10-Q · filed 2021-05-06 | $3.69B derived: sum of 2 quarters · filed 2021-05-06 | $5.44B derived: sum of 3 quarters · filed 2021-05-06 | $7.01B derived: sum of 4 quarters · filed 2021-05-06 | ||||
| 2019-12-31 | $1.86B 10-K · filed 2021-02-08 | $2.17B 10-K · filed 2020-02-07 | $3.61B derived: sum of 2 quarters · filed 2021-02-08 | $5.18B derived: sum of 3 quarters · filed 2021-02-08 | $6.56B 10-K · filed 2022-02-07 | $7.86B 10-K · filed 2020-02-07 | ||
| 2019-09-30 | $1.74B 10-K · filed 2021-02-08 | $2.05B 10-Q · filed 2019-11-05 | $3.32B derived: sum of 2 quarters · filed 2021-02-08 | $4.69B 10-Q · filed 2020-11-05 | $5.69B 10-Q · filed 2019-11-05 | $6.62B derived: sum of 4 quarters · filed 2021-02-08 | ||
| 2019-06-30 | $1.58B 10-K · filed 2021-02-08 | $1.93B 10-Q · filed 2019-08-06 | $2.95B 10-Q · filed 2020-08-05 | $3.65B 10-Q · filed 2019-08-06 | $4.88B derived: sum of 3 quarters · filed 2021-02-08 | $6.54B derived: sum of 4 quarters · filed 2021-02-08 | ||
| 2019-03-31 | $1.37B 10-K · filed 2021-02-08 | $1.71B 10-Q · filed 2019-05-07 | $3.30B derived: sum of 2 quarters · filed 2021-02-08 | $4.96B derived: sum of 3 quarters · filed 2021-02-08 | $6.57B derived: sum of 4 quarters · filed 2021-02-08 | |||
| 2018-12-31 | $1.93B 10-K · filed 2020-02-07 | $3.59B derived: sum of 2 quarters · filed 2020-02-07 | $5.20B derived: sum of 3 quarters · filed 2020-02-07 | $5.15B 10-K · filed 2021-02-08 | $6.71B 10-K · filed 2019-02-07 | |||
| 2018-09-30 | $1.66B 10-K · filed 2020-02-07 | $1.66B 10-Q · filed 2018-11-06 | $3.27B derived: sum of 2 quarters · filed 2020-02-07 | $4.78B 10-Q · filed 2019-11-05 | $4.78B 10-Q · filed 2018-11-06 | $6.37B derived: sum of 4 quarters · filed 2020-02-07 | ||
| 2018-06-30 | $1.61B 10-K · filed 2020-02-07 | $1.61B 10-Q · filed 2018-08-02 | $3.12B 10-Q · filed 2019-08-06 | $3.12B 10-Q · filed 2018-08-02 | $4.70B derived: sum of 3 quarters · filed 2020-02-07 | $6.20B derived: sum of 4 quarters · filed 2020-02-07 | ||
| 2018-03-31 | $1.51B 10-K · filed 2020-02-07 | $3.09B derived: sum of 2 quarters · filed 2020-02-07 | $4.59B derived: sum of 3 quarters · filed 2020-02-07 | $6.06B derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2017-12-31 | $1.58B 10-K · filed 2019-02-07 | $3.08B derived: sum of 2 quarters · filed 2019-02-07 | $4.55B derived: sum of 3 quarters · filed 2019-02-07 | $5.87B 10-K · filed 2020-02-07 | ||||
| 2017-09-30 | $1.50B 10-K · filed 2019-02-07 | $1.50B 10-Q · filed 2018-11-06 | $2.97B derived: sum of 2 quarters · filed 2019-02-07 | $4.29B 10-Q · filed 2018-11-06 | ||||
| 2017-06-30 | $1.47B 10-K · filed 2019-02-07 | $1.47B 10-Q · filed 2018-08-02 | $2.79B 10-Q · filed 2018-08-02 | |||||
| 2017-03-31 | $1.32B 10-K · filed 2019-02-07 | |||||||
| 2016-12-31 | $4.86B 10-K · filed 2019-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |